Proof-of-concept study data on CAD treatment expected later this year
Initial results from a planned proof-of-concept clinical trial testing Annexon Biosciences’ treatment candidate ANX1502 in people with cold agglutinin disease (CAD) are expected in the second half of the year. “We anticipate clinical proof-of-concept data from our novel oral inhibitor ANX1502 later in the year,” Douglas Love, president…